Main Content

Gene Biotherapeutics is a publicly-traded, clinical development-stage biotechnology company engaged in the clinical advancement and commercialization of DNA-based biotherapeutics, primarily for the treatment of cardiovascular disease.

Clinical Trial

The Phase 3 “AFFIRM” clinical study evaluates Gene Biotherapeutics’ lead product candidate, Generx [Ad5FGF-4], as a one-time administration for the treatment of refractory angina due to late-stage coronary artery disease.

Clinical Trial

Our Science

Gene Biotherapeutics’ angiogenic gene therapy is designed to improve cardiac perfusion (blood flow) and to increase the supply of oxygenated blood by promoting the growth of microvasculature in ischemic cardiac tissue.

Our Science

Generx Product Candidate

Generx [Ad5FGF-4] is engineered to express secreted human fibroblast growth factor-4 (FGF-4) protein, a key regulator of angiogenesis. Generx is administered by an interventional cardiologist during a brief procedure similar to a diagnostic angiogram.


Take a moment to answer these few simple questions to see if you're a candidate for the clinical study.

Do you experience chest pain (angina) due to heart disease?

Do you take anti-anginal medication (e.g. nitroglycerin, beta blocker, ACE inhibitors?)?

Have you ever been prescribed Ranexa?

Do you still experience angina despite taking medication?

Does angina limit your physical activity and quality of life?

Have you had a bypass surgery or stent procedure and continue to have angina?

Do you have more than 3 angina attacks a week?

If you answered Yes to any of these questions, please visit to learn more about our Phase 3 AFFIRM Clinical Study

Visit Now
GBT Scientific American
Gene Therapy to Heal Hearts

Read Our Story

Experience our Look Book in 30 seconds.